11-13 June 2019

 

Formosa Laboratories

Formosa Laboratories, a globally-recognized generic API supplier, is approved by regulatory authorities worldwide, including the EMEA, USFDA, PMDA, and COFEPRIS.  Our ado-trastuzumab emtansine biosimilar, co-developed with Formosa Pharmaceuticals, has demonstrated high similarity to Kadcyla®.  We target an IND-ready status in 2019Q1 and currently are seeking strategic partnerships for clinical development worldwide.  With a comprehensive ADC platform specializing in high-potency bioconjugation, Formosa Laboratories offers customized solutions of mAb, linker, payload, DS, and DP, for your ADC.